1-9 of 9
Fiona Miall
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Bendamustine Plus Brentuximab Has Superior Efficacy to Brentuximab Monotherapy As Third-Line Treatment for Classical Hodgkin Lymphoma: A Real-World, Multicentre UK Analysis

Rohan Shotton, Amy A Kirkwood, Michael Northend, Dina Fathoala, Kieran Burton, Graeme Ferguson, Laura Aiken, Caroline Shrubsole, Lauren Henry, Mary Owen, Rebecca Oliver, Nicolas Martinez-Calle, Astrid Etherington, Eve Gallop-Evans, Cathy Burton, Fiona Miall, Wendy Osborne, Rifca Le Dieu, Pamela McKay, Satyen H Gohil, Graham P. Collins, Elizabeth H Phillips
Journal: Blood
Blood (2023) 142 (Supplement 1): 6173.
https://doi.org/10.1182/blood-2023-186601
Published: 2023
Journal Articles

A Phase Ib/II Study of Polatuzumab Vedotin Plus Obinutuzumab and Lenalidomide in Patients with Relapsed/Refractory Follicular Lymphoma: Final Analysis and Progression-Free Survival Update

Catherine S. Diefenbach, Brad S. Kahl, Lalita Banerjee, Andrew K. McMillan, Fiona Miall, Javier Briones, Raul Cordoba, John M. Burke, Jamie Hirata, Sunil Sharma, Lisa Musick, Pau Abrisqueta Costa
Journal: Blood
Blood (2022) 140 (Supplement 1): 2286–2288.
https://doi.org/10.1182/blood-2022-157720
Published: 2022
Journal Articles

Long Term Follow-up of International Randomised Phase 3 Study of Rituximab Versus a Watch and Wait Approach for Patients with Asymptomatic, Low Tumour Burden Follicular Lymphoma Shows Rituximab Is Highly Effective at Delaying Time to New Treatment without Detrimental Impact Following Next Line of Therapy

Michael Northend, William Wilson, Laura Clifton-Hadley, Zaynab Rana, Tanya-Louise Martin, Moya Young, Fiona Miall, David Cunningham, Jan Walewski, Burhan Ferhanoglu, Amanda Johnston, John F. Seymour, David C. Linch, Kirit M. Ardeshna
Journal: Blood
Blood (2022) 140 (Supplement 1): 1456–1458.
https://doi.org/10.1182/blood-2022-156790
Published: 2022
Journal Articles

Timing of high-dose methotrexate CNS prophylaxis in DLBCL: a multicenter international analysis of 1384 patients

Matthew R. Wilson, Toby A. Eyre, Amy A. Kirkwood, Nicole Wong Doo, Carole Soussain, Sylvain Choquet, Nicolás Martinez-Calle, Gavin Preston, Matthew Ahearne, Elisabeth Schorb, Marie-Pierre Moles-Moreau, Matthew Ku, Chiara Rusconi, Jahanzaib Khwaja, Mayur Narkhede, Katharine L. Lewis, Teresa Calimeri, Eric Durot, Loïc Renaud, Andreas Kiesbye Øvlisen, Graham McIlroy, Timothy J. Ebsworth, Johnathan Elliot, Anna Santarsieri, Laure Ricard, Nimish Shah, Qin Liu, Adam S. Zayac, Francesco Vassallo, Laure Lebras, Louise Roulin, Naelle Lombion, Kate Manos, Ruben Fernandez, Nada Hamad, Alberto Lopez-Garcia, Deirdre O'Mahony, Praveen Gounder, Nathalie Forgeard, Charlotte Lees, Kossi Agbetiafa, Tim Strüßmann, Thura Win Htut, Aline Clavert, Hamish Scott, Anna Guidetti, Brett R. Barlow, Emmanuelle Tchernonog, Jeffery Smith, Fiona Miall, Christopher P. Fox, Chan Y. Cheah, Tarec Christoffer El Galaly, Andrés J.M. Ferreri, Kate Cwynarski, Pamela McKay
Journal: Blood
Blood (2022) 139 (16): 2499–2511.
https://doi.org/10.1182/blood.2021014506
Published: 2022
Includes: Supplemental data
Journal Articles

Avenue - Avelumab in the Frontline Treatment of Advanced Classic Hodgkin Lymphoma - a Window Study

Stephen Booth, Eliza Hawkes, Amy A Kirkwood, Sally F Barrington, Patrick G. Medd, Pamela McKay, Ruth Pettengell, Sunil Iyengar, Fiona Miall, John Radford, Cathy Burton, Amit Sud, Nimish Shah, Andrew M Scott, Arzhang Ardavan, Michael Northend, Laura Clifton-Hadley, Richard Jenner, Graham P. Collins
Journal: Blood
Blood (2021) 138 (Supplement 1): 2470.
https://doi.org/10.1182/blood-2021-145189
Published: 2021
Journal Articles

Early Integration of High Dose Methotrexate to Frontline DLBCL Therapy Does Not Impact CNS Relapse Compared to End of Treatment Delivery: A Multicentre International Analysis of 1384 Patients

Matthew R Wilson, Toby A. Eyre, Amy A Kirkwood, Nicole Wong Doo, Carole Soussain, Sylvain Choquet, Nicolas Martinex-Calle, Gavin Preston, Matthew J Ahearne, Elisabeth Schorb, Marie-Pierre Moles-Moreau, Matthew Ku, Chiara Rusconi, Jahanzaib Khwaja, Mayur Narkhede, Katharine L Lewis, Teresa Calimeri, Eric Durot, Loic Renaud, Andreas Kiesbye Øvlisen, Graham McIlroy, Tim Ebsworth, Johnathon Elliot, Anna Santarsiere, Laure Ricard, Nimish Shah, Qin Liu, Adam Zayac, Francesco Vassallo, Laure Lebras, Louise Roulin, Naelle Lombion, Kate Manos, Ruben Fernandez, Nada Hamad, Alberto Lopez-Garcia, Deirdre O'Mahony, Praveen Gounder, Nathalie Forgeard, Charlotte Lees, Kossi Agbetiafa, Tim Strüßmann, Thura Win Htut, Aline Clavert, Hamish W Scott, Anna Guidetti, Brett R Barlow, Jeffrey Smith, Tarec Christoffer El-Galaly, Chan Yoon Cheah, Andres JM Ferreri, Fiona Miall, Christopher P Fox, Kate Cwynarski, Pamela McKay
Journal: Blood
Blood (2021) 138 (Supplement 1): 452.
https://doi.org/10.1182/blood-2021-144820
Published: 2021
Journal Articles

Polatuzumab Vedotin Plus Obinutuzumab and Lenalidomide in Patients With Relapsed/Refractory Follicular Lymphoma: Primary Analysis of the Full Efficacy Population in a Phase Ib/II Trial

Catherine Diefenbach, MD, Brad S. Kahl, MD, Lalita Banerjee, FRCPath, Andrew K McMillan, FRCP, Fiona Miall, MD FRCPath, MRCP, BMBS, Javier Briones, MD PhD, Raul Cordoba, MD PhD, Jamie Hirata, PharmD, YiMeng Chang, MSc, Lisa Musick, PharmD, Pau Abrisqueta, MD PhD
Journal: Blood
Blood (2019) 134 (Supplement_1): 126.
https://doi.org/10.1182/blood-2019-123669
Published: 2019
Journal Articles

A Variety of T-Cell Subsets Contribute to CD4+ T-Cell Infiltration in Diffuse Large B-Cell Lymphoma and Both Total CD4+ and CD4+FoxP3+ T-Cell Numbers Predict Clinical Outcome,

Matthew J Ahearne, MBChB MRCP, Kaljit S Bhuller, MBChB MRCP, Roger Hew, MBChB, Giovanna Roncador, Martin J.S. Dyer, MA, DPhil, Daniel B. Kennedy, Fiona Miall, MD, Simon D. Wagner, MBBS, PhD, FRCP
Journal: Blood
Blood (2011) 118 (21): 3684.
https://doi.org/10.1182/blood.V118.21.3684.3684
Published: 2011
Journal Articles

An Intergroup Randomised Trial of Rituximab Versus a Watch and Wait Strategy In Patients with Stage II, III, IV, Asymptomatic, Non-Bulky Follicular Lymphoma (Grades 1, 2 and 3a). A Preliminary Analysis

Kirit M Ardeshna, MD, Wendi Qian, Paul Smith, June Warden, Lindsay Stevens, Christopher FE Pocock, MD, PhD, Fiona Miall, MD, David Cunningham, MD, John Davies, MD, Jan Walewski, A. Burhan Ferhanoglu, MD, Ken Bradstock, MB, PhD, David C Linch, MD, FMedSci
Journal: Blood
Blood (2010) 116 (21): 6.
https://doi.org/10.1182/blood.V116.21.6.6
Published: 2010